Yaron Shargall News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Yaron shargall. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Yaron Shargall Today - Breaking & Trending Today
Study quantifies the true incidence of venous thromboembolism post esophagectomy A new study presented today at the AATS 101st Annual Meeting, found that the percentage of patients undergoing esophagectomy for cancer who suffer Venous Thromboembolism (VTE) post-operatively is much higher than previously reported, with as many as 24 percent suffering from Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE). Six-month mortality for patients with VTE was 17.6 percent compared to 2.1 percent for those without. Venous Thromboembolism (VTE) is a common, potentially preventable post-operative complication leading to significant morbidity and mortality. Esophagectomy patients are amongst the highest risk groups for VTE due to disease burden, magnitude of surgery and high rate of perioperative morbidity. The study aimed to quantify the true incidence of VTE post esophagectomy, associated risk factors, and the impact of VTE on patients outcomes. ....
Up to 24 pc of esophagectomy patients can develop VTE post-operatively: Study ANI | Updated: May 02, 2021 07:33 IST Boston (Massachusetts) [US], May 2 (ANI): A new study presented at the AATS 101st Annual Meeting, found that the percentage of patients undergoing esophagectomy for cancer who suffer Venous Thromboembolism (VTE) post-operatively is much higher than previously reported, with as many as 24 per cent suffering from Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE). The novel study pointed out that six-month mortality for patients with VTE was 17.6 per cent compared to 2.1 per cent for those without. Venous Thromboembolism (VTE) is a common, potentially preventable post-operative complication leading to significant morbidity and mortality. Esophagectomy patients are amongst the highest risk groups for VTE due to disease burden, the magnitude of surgery and high rate of perioperative morbidity. The study aimed t ....
E-Mail Boston, MA (May 1, 2021) - A new study presented today at the AATS 101st Annual Meeting, found that the percentage of patients undergoing esophagectomy for cancer who suffer Venous Thromboembolism (VTE) post-operatively is much higher than previously reported, with as many as 24 percent suffering from Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE). Six-month mortality for patients with VTE was 17.6 percent compared to 2.1 percent for those without. Venous Thromboembolism (VTE) is a common, potentially preventable post-operative complication leading to significant morbidity and mortality. Esophagectomy patients are amongst the highest risk groups for VTE due to disease burden, magnitude of surgery and high rate of perioperative morbidity. The study aimed to quantify the true incidence of VTE post esophagectomy, associated risk factors, and the impact of VTE on patients outcomes. ....
E-Mail Boston, MA (April 30, 2021) - A new set of guidelines, developed by AATS and ESTS (European Society for Thoracic Surgery) presented today at the AATS 101st Annual Meeting, recommends a 30-day course of Venous Thromboembolism (VTE) prophylaxis post-discharge for patients undergoing surgical resection for lung or esophagus cancer. The AATS and ESTS formed a multidisciplinary guideline panel that included broad membership to minimize potential bias when formulating recommendations. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic reviews and meta-analyses. The results are endorsed by the American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis, Inc (ISTH). ....
Novel immunotherapy combination can be highly effective for treating lung cancer McMaster University researchers have established in lab settings that a novel combination of two forms of immunotherapy can be highly effective for treating lung cancer, which causes more deaths than any other form of cancer. The new treatment, yet to be tested on patients, uses one form of therapy to kill a significant number of lung tumor cells, while triggering changes to the tumor that enable the second therapy to finish the job. The first therapy employs suppressed natural killer immune cells by extracting them from patients tumors or blood and supercharging them for three weeks. The researchers condition the cells by expanding and activating them using tumor-like feeder cells to improve their effectiveness before sending them back into battle against notoriously challenging lung tumors. ....